ID   NTUB1/P[14]
AC   CVCL_RW31
SY   NTUB1/P
DR   Wikidata; Q54931134
RX   PubMed=11062746;
RX   PubMed=12137851;
CC   Population: Chinese; Taiwan.
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_RW29 ! NTUB1
SX   Female
AG   70Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 19-12-24; Version: 7
//
RX   PubMed=12137851; DOI=10.1016/S0090-4295(02)01699-0;
RA   Pu, Yeong-Shiau
RA   Hour, Tzyh-Chyuan
RA   Chen, Jun
RA   Huang, Chao-Yuan
RA   Guan, Jing-Yi
RA   Lu, Shiu-Hui
RT   "Cytotoxicity of arsenic trioxide to transitional carcinoma cells.";
RL   Urology 60:346-350(2002).
//
RX   PubMed=11062746;
RA   Hour, Tzyh-Chyuan
RA   Chen, Jun
RA   Huang, Chao-Yuan
RA   Guan, Jing-Yi
RA   Lu, Shiu-Hui
RA   Hsieh, Chang-Yao
RA   Pu, Yeong-Shiau
RT   "Characterization of chemoresistance mechanisms in a series of
RT   cisplatin-resistant transitional carcinoma cell lines.";
RL   Anticancer Res. 20:3221-3225(2000).
//